Amgen expects generic biologics
Executive Summary
"Generic biologics will happen and I think we'll see them in Europe first," Amgen CEO Kevin Sharer told investors Feb. 25. The exec noted that generic biologics are "profoundly different" from conventional generic drugs, citing the need to conduct clinical trials and the larger required investment in manufacturing facilities as examples. Sharer expects that Amgen's Epogen (epoetin alfa) in Europe would be the company's first product to face generic competition; however, the CEO said, "from our patent lives here in the U.S. and for the newer products in Europe, it's a long way out for us"...
You may also be interested in...
BIO Likes EU Model For Follow-On Biologics; Standards Are “Appropriate”
The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.